Outcomes

The available evidence on LL-37 outcomes is limited and comes primarily from observational studies and mechanistic research, with very few completed clinical trials reporting measurable clinical endpoints.

Clinical Biomarker Changes

Periodontal Disease Context:

One completed observational study (NCT04404335) examined LL-37 levels as a biomarker in periodontal disease treatment, though specific quantitative results are not available from the evidence provided
A 2026 study found associations between vitamin D insufficiency, periodontitis, and gingival crevicular fluid (GCF) LL-37 levels in diabetes patients with periodontitis, suggesting LL-37 may serve as a measurable biomarker in this context

Vitamin D Relationship:

A completed study (NCT03923218) investigated effects of smoking and vitamin D3 supplementation on LL-37 levels, indicating LL-37 can be measured as a responsive biomarker, though specific numerical outcomes are not provided in the available evidence

Preclinical Mechanistic Outcomes

Recent research reports several mechanistic effects of LL-37:

Anti-cancer Activity:

LL-37 demonstrated inhibition of osteosarcoma progression through suppression of SQLE-mediated cholesterol synthesis via the PTEN/AKT/mTOR pathway (2026 study)

Anti-inflammatory Effects:

Research on oroxylin A showed modulation of LL-37-generated rosacea-like skin inflammation through SIRT3-SOD2-NF-κB signaling pathways, suggesting LL-37 levels correlate with measurable inflammatory outcomes

Evidence Limitations

The strength of evidence for clinical outcomes is very limited. Most available data comes from:

Mechanistic studies without clinical endpoints
Observational studies measuring LL-37 as a biomarker rather than therapeutic outcomes
Multiple withdrawn or terminated clinical trials (including vitamin D studies that would have assessed LL-37 levels)

Notable gaps: There are no completed randomized controlled trials directly testing LL-37 as a therapeutic intervention with reported clinical efficacy outcomes. The available evidence primarily demonstrates that LL-37 levels can be measured and may correlate with disease states, but does not establish therapeutic efficacy or optimal dosing parameters.

This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers for personalized medical guidance.

LL-37

Member access required